A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the clinical activity of interferon beta-1a
in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this
study are to determine (i) the safety and tolerability of interferon beta-1a in participants
with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the
Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.